OTCMKTS:IGXT IntelGenx Technologies (IGXT) Stock Price, News & Analysis $0.17 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.09▼$0.22VolumeN/AAverage Volume102,577 shsMarket Capitalization$29.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get IntelGenx Technologies alerts: Email Address Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About IntelGenx Technologies Stock (OTCMKTS:IGXT)IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More IGXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGXT Stock News HeadlinesAugust 18, 2024 | benzinga.comIntelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News SummaryJuly 20, 2024 | finanznachrichten.deIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 19, 2024 | globenewswire.comIntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 3, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJune 11, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessMay 28, 2024 | globenewswire.comIntelGenx Obtains Court-Approval of a Sale and Investment Solicitation ProcessMay 17, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…May 17, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 8, 2024 | globenewswire.comIntelGenx Announces Voting Results on Election of DirectorsApril 8, 2024 | finance.yahoo.comIntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical TrialApril 8, 2024 | globenewswire.comIntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical TrialApril 5, 2024 | globenewswire.comIntelGenx Updates Status of Buprenorphine Buccal Film ANDAMarch 23, 2024 | seekingalpha.comIntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | insidermonkey.comIntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | investorplace.comIGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023March 21, 2024 | globenewswire.comIntelGenx Reports Fourth Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2020Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IGXT CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,930,000.00 Net Margins-1,049.48% Pretax Margin-1,049.48% Return on EquityN/A Return on Assets-158.32% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.12 Sales & Book Value Annual Sales$1.04 million Price / Sales28.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.39Miscellaneous Outstanding Shares174,658,000Free Float101,214,000Market Cap$29.17 million OptionableNot Optionable Beta2.47 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Dwight Gorham (Age 66)Chief Executive Officer Comp: $230.56kMr. André Godin C.A. (Age 60)CPA, CA, CPA, President & CFO Comp: $261.62kMr. Tommy Kenny J.D. (Age 37)L.L.B., M.Sc., Senior VP & General Counsel Comp: $152.62kMs. Nadine Paiement M.Sc. (Age 47)Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp Comp: $156.5kMs. Karen Kalayajian CPA (Age 44)Vice President of Finance & Administration Stephen KilmerInvestor Relations OfficerMs. Ingrid Zerbe (Age 70)Corporate Secretary Zenoz Nina PourhassanVP of Quality Operations of SubsidiaryMore ExecutivesKey CompetitorsINmune BioNASDAQ:INMBInventivaNASDAQ:IVAAdageneNASDAQ:ADAGNuvectis PharmaNASDAQ:NVCTPuma BiotechnologyNASDAQ:PBYIView All Competitors IGXT Stock Analysis - Frequently Asked Questions How have IGXT shares performed this year? IntelGenx Technologies' stock was trading at $0.1381 at the beginning of the year. Since then, IGXT stock has increased by 20.9% and is now trading at $0.1670. View the best growth stocks for 2024 here. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The business had revenue of $0.51 million for the quarter. How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL) and This page (OTCMKTS:IGXT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IntelGenx Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.